The availability of oxygen is a crucial prognostic indicator for outcomes pertinent to many
chronic diseases. Accordingly, interventions that might increase oxygen availability have
obvious beneficial clinical application. In this regard, Respirogen Micro-Oxygen (RMO)
technology holds considerable promise. Data from experimental animal models of lung injury
suggest administration of RMO is a feasible method to deliver oxygen in a manner independent
of pulmonary function. Our ultimate long-term goal is to provide a product that can be used
to deliver oxygen to humans experiencing respiratory distress and pulmonary dysfunction In
this first exploratory study, our goal is to begin to understand the physiological responses
to enteral (rectal) delivery of RMO in low-oxygen environments in healthy adults at rest.